ENVB vs EPRX

Enveric Biosciences, Inc. vs Eupraxia Pharmaceuticals Inc. — Valuation Comparison 2026

ENVB

Biotechnology
Enveric Biosciences, Inc.
Quality
3.8
out of 10
Value Trap
39
LOW
Price
$2.32
Last close
Models
9/13
Active
VS

EPRX

Biotechnology
Eupraxia Pharmaceuticals Inc.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$7.38
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ENVB Fair ValueENVB Upside EPRX Fair ValueEPRX Upside
Bayesian DCF Intrinsic $1.35 -41.8% $1.95 -73.5%
Earnings Power Value Intrinsic $2.37 -40.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $1.43 -38.4% $4.13 -42.5%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENVB vs EPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENVB vs EPRX — Which Stock Is More Undervalued?

ENVB scores higher with a 3.8/10 quality rating vs EPRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enveric Biosciences, Inc. (ENVB) and Eupraxia Pharmaceuticals Inc. (EPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENVB currently trades at $2.32 with a QOC of 3.8/10, while EPRX trades at $7.38 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).